Cargando…
Triple Therapy for Cystic Fibrosis (Elexacaftor, Tezacaftor, and Ivacaftor): Desensitization After Skin Rash
Cystic fibrosis (CF) is an autosomal recessive disorder of the CF transmembrane conductance regulator (CFTR) gene. CFTR modulators are novel approved therapies, and triple therapy with elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) is the current gold standard for patients with at least one F508del...
Autores principales: | Santos, Ana Isabel, Pacheco, Joana, Cemlyn-Jones, Jessica, Gamboa, Fernanda |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10613531/ https://www.ncbi.nlm.nih.gov/pubmed/37905296 http://dx.doi.org/10.7759/cureus.46228 |
Ejemplares similares
-
Elexacaftor/tezacaftor/ivacaftor for cystic fibrosis
Publicado: (2021) -
Impact of elexacaftor/tezacaftor/ivacaftor on depression and anxiety
in cystic fibrosis
por: Zhang, Lijia, et al.
Publicado: (2022) -
ICER releases evidence report on elexacaftor/tezacaftor/ivacaftor for cystic fibrosis
Publicado: (2020) -
Elexacaftor–Tezacaftor–Ivacaftor improves exercise capacity in adolescents with cystic fibrosis
por: Causer, Adam J., et al.
Publicado: (2022) -
Elexacaftor/tezacaftor/ivacaftor corrects monocyte microbicidal deficiency in cystic fibrosis
por: Cavinato, Luca, et al.
Publicado: (2023)